Not yet recruiting
MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer
NCT07934121· Phase 2· Tongji Hospital· Source
Not yet recruiting
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537· Phase 1/2· Shenzhen Fosun Kairos Biotechnology Co., Ltd.· Source
Contact: Gang Xu, Medical Doctor
Not yet recruiting
Tongji NADs Cohort
NCT07333196· Tongji Hospital· Source
Recruiting
Durvalumab as Consolidation for Patients LS-SCLC
NCT07055581· Phase 2· Qian Chu· Source
Contact: Qian Chu, Head of the Thoracic Cancer De
Not yet recruiting
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063· Phase 1/2· Shanghai Gynecologic Oncology Group· Source
Contact: Qinglei Gao, MD, PHD
Recruiting
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
NCT06885957· Tongji Hospital· Source
Contact: Ke Shang, PhD
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743· Phase 3· BeOne Medicines· Source
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041· Phase 3· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Aiguo Liu, MD
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Aiguo Liu, PhD
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Aiguo Liu, PhD
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238· Phase 2/3· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Aiguo Liu, PhD
Recruiting
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
NCT07359235· Phase 1· Tongji Hospital· Source
Contact: Zheng Liu PhD
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
NCT06474507· Tongji Hospital· Source
Contact: Ke Shang, PhD
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· Phase 1/2· BeOne Medicines· Source
Contact: Study Director
Recruiting
The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women
NCT06556342· Tongji Hospital· Source
Contact: Qinglei Gao, PhD, MD
Recruiting
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
NCT06552598· Phase 1· Tongji Hospital· Source
Contact: Qinglei Gao, PhD, MD
Active, not recruiting
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425· Tongji Hospital· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037· Phase 2· BeOne Medicines· Source
Recruiting
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
NCT06000956· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Chang Shu
Active, not recruiting
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377· Phase 2/3· BeOne Medicines· Source
Active, not recruiting
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955· Phase 1/2· BeiGene· Source
Active, not recruiting
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994· Phase 2· BeiGene· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843· Phase 1/2· BeOne Medicines· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Recruiting
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
NCT05206890· Tongji Hospital· Source
Contact: Qinglei Gao, PhD, MD
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Active, not recruiting
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297· Phase 3· BeOne Medicines· Source
Active, not recruiting
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977· Phase 3· BeiGene· Source
Active, not recruiting
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230· Phase 3· BeiGene· Source